Evidence map›Paper›PMID 33254510›Full record

ArticleMedical hypotheses2020

Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?

Huseyin Avcilar, Ahmet Eken

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Proteomics: A Tool to Study Platelet Function.International journal of molecular sciences · 2021
    Review
  4. Review
  5. Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Huseyin AvcilarErciyes University, Immunology Department, Faculty of Medicine, Kayseri, Turkey. Electronic address: havcilar13@gmail.com.
Ahmet EkenBetul-Ziya Eren Genome and Stem Cell Center, Kayseri, Turkey; Erciyes University, Medical Biology Department, Faculty of Medicine, Kayseri, Turkey. Electronic address: ahmet.eken@gmail.com.
Erciyes University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toll-like receptor 7 is critical in recognition of single strand RNA viruses, including SARS CoV-2, and generation of anti-viral immunity. Coronaviruses evolved strategies to dampen the host immunity. Herein, we discuss the potential use of TLR7 agonists in the early stages of COVID-19 treatment.

Indexed as

COVID-19 Drug TreatmentAdjuvants, ImmunologicAntiviral AgentsCOVID-19HumansImiquimodImmunity, InnateModels, ImmunologicalPandemicsSARS-CoV-2Skin CreamToll-Like Receptor 7Adjuvants, ImmunologicAntiviral AgentsImiquimodTLR7 protein, humanToll-Like Receptor 7COVID-19ImiquimodSARS CoV-2TLR7

Identifiers

PMID33254510
PMCPMC7434307
OpenAlexW3049042050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.